Group items tagged

Abirapro 120 Tablets Suppliers in India, Abirapro contains Abiraterone Acetate. Abirapro is manufactured by Glenmark Pharma. This Medicine is available in 250 Mg Tablets Form. We are leading suppliers & exporters of "Abirapro 250Mg" in China, Russia, Hongkong, Bulgaria, Romania, India. And the largest suppliers-exporters of "Glenmarks Onkos" medicines & provide you the best price on Abirapro Abiraterone acetate. The lowest price sellers, suppliers, distributors & Exporters from Delhi-India. Abirapro 250 mg Tablet is an anticancer drug basically used in men along with another drug called prednisone for the treatment of prostate cancer that has spread to other parts of the body. As It is generally used in patients who are not responding to other treatment options. Abirapro 120 Tablets Suppliers in India Abirapro 120 Tablets Suppliers in India, Abirapro 120 Tablets Suppliers in Russia Buy Online Abirapro 120 Tablets Buy Now Description: Brand name - Abirapro Generic name - Abiraterone acetate Strength - 250 Mg Form - Tablets Packing - 1 X 120 Manufactured by - Glenmark (onkos) it's a Glenmarks Oncolgy anti cancer Division Usage : Clinical Packaging Type : Box Expert Advice:Well "Abirapro 250 mg Tablet" treats prostate cancer that has spread to other parts of the body. Usually it can be taken with another medicine called prednisolone to reduce unwanted side effects. Always remember that it must be taken on an empty stomach. Don't eat any food for at least 2 hours before or 1 hour after your dose. How It Works: Take Abirapro 250 mg Tablet as instructed by your doctor. Don't take it in larger amounts as advised/prescribed. Immediately Consult the doctor if you experience any undesirable side effects. Be sure that the treatment course is completed. Don't stop the use of this medicine/tablet without consulting your doctor. Note: Abirapro 250Mg is a prescription Drug and should be used under Proper Medical Guidance and Advice. Do no

The National Pharmacy Association (NPA) and BeWell are working together to help provide efficiencies and productivity that address the growing pressures within community pharmacy. BeWell's Pharmacy Management Platform provides robust solutions that include Patient Relationship Management, Omnichannel Communications and Engagement, Services and Bookings Management, access to patient records, NHS Login supported Patient Application, and repeat prescription capabilities for Pharmacy Website and Patient App that include integrations with Surgery Online Services. This single interoperable platform is also integrated with pharmacy PMRs, connecting back office and administrative functions with front-of-house digital patient experiences. In line with the NPA's vision, BeWell has taken a leading role in formulating a unique ecosystem of pharmacy partners uniting marketing agencies, PGD-based service providers, and delivery method partners - integrating their capabilities within the BeWell platform.

The Medicines and Healthcare products Regulatory Agency (MHRA) and the Committees of Advertising Practice (CAP) have issued a joint enforcement notice about the 'illegal' advertising of Kenalog injections on digital platforms. The notice warns all organisations offering Kenalog as a 'hay fever treatment' to stop advertising it in any of their social media or website advertising. "Kenalog is a prescription-only medicine (POM), which must not be directly or indirectly advertised to the public. Kenalog is not licensed for the treatment of hay fever in the UK, although it is offered by some beauty and aesthetics clinics, under the personal responsibility of an individual prescriber, and advertised widely on social media," said MHRA. "Now, advertisers must ensure that all references to Kenalog in the text, images or emojis on social media are removed, as well as commonly-used descriptive phrases for the jab such as 'hay fever injection' or hay fever jab' or any account names, testimonials or memes by 29 August 2022." After this date, the CAP's compliance team will remove non-compliant ads using targeted software and those who continue to promote it may be referred to the MHRA for further enforcement action.

The General Pharmaceutical Council (GPhC) today decided to convene a new group, involving all the key stakeholders, focused on assurance of practice post-registration. The decision in today's (9 December) council meeting follows the recommendation of a working group chaired by council member and pharmacist Aamer Safdar on the role of the regulator in post-registration education and training. The new group will be tasked with articulating a set of guiding principles where patient safety is the overarching priority, after carrying out a horizon scanning exercise to pull together an understanding of the system wide approach currently in place. The working group noted that the wider approach, in relation to regulation of post-registration practice and not simply education and training, may require the GPhC reviewing and developing its own control measures, and involving patients and the public in the next stages of work. Reviewing the work on online pharmacy services, the council meeting supported the regulator's plans to continue to require pharmacy websites to be arranged so that a person cannot choose a prescription only medicine and its quantity before there has been an appropriate consultation with a prescriber.

The Pharmaceutical Services Negotiating Committee has announced that the Department of Health and Social Care (DHSC) has granted final price concessions to further items for the month of November 2021. A price concession only applies for the month in which it is granted. No additional prescription endorsement are required as the new price is automatically applied by the NHS BSA to all items submitted for payment in the same month for which a price concession is granted. Contractors can find information and learn about the process involved on PSNC's website. Check pharmacy business website for price concession list november 2021.

Professional translators recreate texts, not simply matching word-for-word, but understanding the underlying meaning, purpose, and interpretation of the original language, and reproduce it using appropriate terminology and structure to ensure there is no potential for misunderstanding. An experienced technical translator addresses conventions to ensure the meaning of the information is preserved, using medical expertise and quality review processes to adapt documentation to meet the needs of patients, medical practitioners, and peers. Attention to detail is fundamental to medical translations and a non-technical translation is an unacceptably high risk for any organisation involved in publishing or circulating medical information of any kind. WHAT IS MEDICAL TRANSLATION? Medical translation is a technical process where capable translators reproduce content or documentation used anywhere in the medical industry, including psychiatry, systematic reviews, tuition and training, patient communications for pharmaceutical translation services. Important clinical trial translations can include labelling, prescriptions, medical devices and patient records, with millions of medicines and treatments used globally and written in multiple languages. Qualified medical translators must have exceptional linguistic skills but also a thorough understanding of medical sciences in all the native languages concerned. However, the complexity of translating one label or one document into several languages can mean that organisations may assume a simple translation is sufficient - when it is anything but!